Effects of Resveratrol on Liver Function Tests in Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis of Randomized Controlled Trials

Background. Some studies have shown that resveratrol may prevent, delay, or treat liver damage. This study aimed to provide up-to-date evidence regarding the effect of resveratrol on the liver enzymes (ALT & AST) in NAFLD patients. We conducted a systematic review and meta-analysis to evalua...

Full description

Bibliographic Details
Main Authors: P. Ebrahimpour, M. Karamian, A. Sharifi
Format: Article
Language:Russian
Published: Gastro LLC 2024-03-01
Series:Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:
Online Access:https://www.gastro-j.ru/jour/article/view/921
_version_ 1797245139482050560
author P. Ebrahimpour
M. Karamian
A. Sharifi
author_facet P. Ebrahimpour
M. Karamian
A. Sharifi
author_sort P. Ebrahimpour
collection DOAJ
description Background. Some studies have shown that resveratrol may prevent, delay, or treat liver damage. This study aimed to provide up-to-date evidence regarding the effect of resveratrol on the liver enzymes (ALT & AST) in NAFLD patients. We conducted a systematic review and meta-analysis to evaluate the effect of resveratrol on liver enzymes in patients with NAFLD by searching various databases for published RCTs.Methods. A systematic search in PubMed, Scopus, and Web of Science was performed up to September 2023. This systematic review and meta-analysis included all the RCT studies assessing resveratrol supplements on serum AST and/or ALT in NAFLD patients. The effect was presented as a mean difference and 95 % confidence interval (CI) in a random-effects model.Results. Finally, six eligible randomized controlled trials consisting of 256 patients were found. Resveratrol had no significant effect on serum ALT (Mean diff = 3.30 IU/L; 95 % CI: –2.34, 8.94; p = 0.25) and AST (Mean diff = 0.07 IU/L; 95 % CI: –2.96, 3.10; p = 0.96) concentrations. Moreover, subgroup analysis revealed that neither resveratrol dose nor intervention duration had any significant effect on the serum ALT and AST levels.Conclusion. The current evidence shows that resveratrol supplementation did not affect liver enzymes in NAFLD patients.
first_indexed 2024-04-24T19:22:09Z
format Article
id doaj.art-a9129edc6bb74d28b197187d705b8dda
institution Directory Open Access Journal
issn 1382-4376
2658-6673
language Russian
last_indexed 2024-04-24T19:22:09Z
publishDate 2024-03-01
publisher Gastro LLC
record_format Article
series Российский журнал гастроэнтерологии, гепатологии, колопроктологии
spelling doaj.art-a9129edc6bb74d28b197187d705b8dda2024-03-25T16:53:11ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732024-03-01341374610.22416/1382-4376-2024-34-1-37-46627Effects of Resveratrol on Liver Function Tests in Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis of Randomized Controlled TrialsP. Ebrahimpour0M. Karamian1A. Sharifi2Hamadan University of Medical SciencesHamadan University of Medical SciencesHamadan University of Medical SciencesBackground. Some studies have shown that resveratrol may prevent, delay, or treat liver damage. This study aimed to provide up-to-date evidence regarding the effect of resveratrol on the liver enzymes (ALT & AST) in NAFLD patients. We conducted a systematic review and meta-analysis to evaluate the effect of resveratrol on liver enzymes in patients with NAFLD by searching various databases for published RCTs.Methods. A systematic search in PubMed, Scopus, and Web of Science was performed up to September 2023. This systematic review and meta-analysis included all the RCT studies assessing resveratrol supplements on serum AST and/or ALT in NAFLD patients. The effect was presented as a mean difference and 95 % confidence interval (CI) in a random-effects model.Results. Finally, six eligible randomized controlled trials consisting of 256 patients were found. Resveratrol had no significant effect on serum ALT (Mean diff = 3.30 IU/L; 95 % CI: –2.34, 8.94; p = 0.25) and AST (Mean diff = 0.07 IU/L; 95 % CI: –2.96, 3.10; p = 0.96) concentrations. Moreover, subgroup analysis revealed that neither resveratrol dose nor intervention duration had any significant effect on the serum ALT and AST levels.Conclusion. The current evidence shows that resveratrol supplementation did not affect liver enzymes in NAFLD patients.https://www.gastro-j.ru/jour/article/view/921resveratrolnon-alcoholic fatty liver diseasealanine transaminaseaspartate aminotransferasesmeta-analysis
spellingShingle P. Ebrahimpour
M. Karamian
A. Sharifi
Effects of Resveratrol on Liver Function Tests in Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis of Randomized Controlled Trials
Российский журнал гастроэнтерологии, гепатологии, колопроктологии
resveratrol
non-alcoholic fatty liver disease
alanine transaminase
aspartate aminotransferases
meta-analysis
title Effects of Resveratrol on Liver Function Tests in Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis of Randomized Controlled Trials
title_full Effects of Resveratrol on Liver Function Tests in Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis of Randomized Controlled Trials
title_fullStr Effects of Resveratrol on Liver Function Tests in Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis of Randomized Controlled Trials
title_full_unstemmed Effects of Resveratrol on Liver Function Tests in Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis of Randomized Controlled Trials
title_short Effects of Resveratrol on Liver Function Tests in Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis of Randomized Controlled Trials
title_sort effects of resveratrol on liver function tests in patients with non alcoholic fatty liver disease a systematic review and meta analysis of randomized controlled trials
topic resveratrol
non-alcoholic fatty liver disease
alanine transaminase
aspartate aminotransferases
meta-analysis
url https://www.gastro-j.ru/jour/article/view/921
work_keys_str_mv AT pebrahimpour effectsofresveratrolonliverfunctiontestsinpatientswithnonalcoholicfattyliverdiseaseasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT mkaramian effectsofresveratrolonliverfunctiontestsinpatientswithnonalcoholicfattyliverdiseaseasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT asharifi effectsofresveratrolonliverfunctiontestsinpatientswithnonalcoholicfattyliverdiseaseasystematicreviewandmetaanalysisofrandomizedcontrolledtrials